GlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a collaboration with Cloud Pharmaceuticals.
UCB is changing the way it conducts some of its research studies, removing the need for patients to attend hospitals by allowing them to take part in virtual clinical trials at home.